文献速递肝病

血液内毒素水平作为非酒精性脂肪性肝病生物标志物:系统评价与荟萃分析

Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-12-05

系统评价与荟萃分析纳入43项研究(其中34项用于荟萃分析),评估非酒精性脂肪性肝病(NAFLD)患者血液内毒素水平。结果显示,单纯性脂肪变性患者血液内毒素水平高于肝脏健康对照(标准化均数差0.86,95%CI 0.62-1.11),非酒精性脂肪性肝炎患者高于非酒精性脂肪肝/非非酒精性脂肪性肝炎患者(标准化均数差0.81,95%CI 0.27-1.35,P=0.0078);内毒素水平升高与C反应蛋白升高相关,且多数情况下与肠道通透性标志物升高平行。结论支持血液内毒素水平作为NAFLD相关诊断生物标志物。

要点

  • 单纯性脂肪变性患者血液内毒素水平高于肝脏健康对照(标准化均数差0.86,95%CI 0.62-1.11)。
  • 非酒精性脂肪性肝炎患者血液内毒素水平高于非酒精性脂肪肝/非非酒精性脂肪性肝炎患者(标准化均数差0.81,95%CI 0.27-1.35,P=0.0078)。
  • 内毒素水平升高与C反应蛋白升高相关,多数情况下与肠道通透性标志物升高平行。

核心结论

  • 结果支持血液内毒素水平作为NAFLD的相关诊断生物标志物,既用于疾病检测也用于疾病进展分期,并可能作为NAFLD中肠道通透性增强的替代标志物。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Embase和Cochrane Library截至2022年1月发表的研究,评估NAFLD患者血液内毒素。
  • 共纳入43项研究,其中34项用于荟萃分析。

主要发现

  • 单纯性脂肪变性患者血液内毒素水平高于肝脏健康对照(标准化均数差0.86,95%CI 0.62-1.11)。
  • 非酒精性脂肪性肝炎患者血液内毒素水平高于非酒精性脂肪肝/非非酒精性脂肪性肝炎患者(标准化均数差0.81,95%CI 0.27-1.35,P=0.0078)。
  • 肝脏脂肪变性和纤维化组织病理学分级更晚期的患者中观察到更高的内毒素水平。
  • 血液内毒素水平升高部分归因于NAFLD患者相比对照的体重指数升高,但在补偿体重指数、代谢状况或肝酶差异后,NAFLD中血液内毒素水平的显著升高仍保留。
  • 血液内毒素水平升高与C反应蛋白浓度升高相关,且多数情况下与肠道通透性标志物升高平行。

关键数值与推荐

  • 单纯性脂肪变性 vs 肝脏健康对照:标准化均数差0.86(95%CI 0.62-1.11)。
  • 非酒精性脂肪性肝炎 vs 非酒精性脂肪肝/非非酒精性脂肪性肝炎:标准化均数差0.81(95%CI 0.27-1.35,P=0.0078)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Growing evidence supports a role of gut-derived metabolites in nonalcoholic fatty liver disease (NAFLD), but the relation of endotoxin levels with gut permeability and NAFLD stage remains unclear. This systematic review with meta-analysis aims to provide further insights. METHODS: PubMed, Embase, and Cochrane Library were searched for studies published until January 2022 assessing blood endotoxins in patients with NAFLD. Meta-analyses and univariate/multivariate meta-regression, as well as correlation analyses, were performed for endotoxin values and potential relationships to disease stage, age, sex, parameters of systemic inflammation, and metabolic syndrome, as well as liver function and histology. RESULTS: Forty-three studies were included, of which 34 were used for meta-analyses. Blood endotoxin levels were higher in patients with simple steatosis vs liver-healthy controls (standardized mean difference, 0.86; 95% confidence interval, 0.62-1.11) as well as in patients with nonalcoholic steatohepatitis vs patients with nonalcoholic fatty liver/non-nonalcoholic steatohepatitis (standardized mean difference, 0.81; 95% confidence interval, 0.27-1.35; P = .0078). Consistently, higher endotoxin levels were observed in patients with more advanced histopathological gradings of liver steatosis and fibrosis. An increase of blood endotoxin levels was partially attributed to a body mass index rise in patients with NAFLD compared with controls. Nevertheless, significant increases of blood endotoxin levels in NAFLD retained after compensation for differences in body mass index, metabolic condition, or liver enzymes. Increases in blood endotoxin levels were associated with increases in C-reactive protein concentrations, and in most cases, paralleled a rise in markers for intestinal permeability. CONCLUSION: Our results support blood endotoxin levels as relevant diagnostic biomarker for NAFLD, both for disease detection as well as staging during disease progression, and might serve as surrogate marker of enhanced intestinal permeability in NAFLD. Registration number in Prospero: CRD42022311166.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Soppert J, Brandt EF, Heussen NM, et al. Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022. PMID: 36470528. doi:10.1016/j.cgh.2022.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。